| |
Research Article
|
|
Antifertility Potentials of Metronidazole in Male Wistar Rats
|
|
A.E. Ligha,
B. Bokolo
and
B.C. Didia
|
| |
ABSTRACT
|
|
There is a growing concern about the decline in the quality
of human sperm in recent years. Following reports by previous studies on the
toxic effects of metronidazole on testicular functions, this study is designed
to investigate further its direct effects on fertility potentials and that of
the introduction of vitamin E and testosterone to metronidazole treated rats.
A total of 105 adult male and 50 female Wistar rats weighing 170±10 g
(70-90 day old) were used for the experiment. The rats were randomly divided
into a control and experimental groups. There were four major groups with 5
subgroups consisting of 5 rats each. Varying doses of metronidazole were used
depending on the experiment. Experiment 1; animals were fed with 15 mg kg-1
of metronidazole, experiment 2, fed with 30 mg kg-1 of metronidazole,
experiment 3, administered with 200 mg kg-1 of metronidazole and
experiment 4, fed with 400 mg kg-1 of metronidazole. Each experimental
group has 5 sub-groups. A: control, B: group fed with the experimental dose,
C: experimental dose with vitamin E, D: experimental dose with testosterone,
E: fed with experimental dose, vitamin E and testosterone and sub-group F, a
reversal group which was left for 8 weeks after cessation of treatment. Parameters
assessed were sperm count/motility, hormonal assay, Fertility test for control
and treated rats were also carried out. Results showed that metronidazole at
the therapeutic dose of 15 mg kg-1 did not have significant negative
effect on the parameters assessed. At the dose of 200 and 400 mg kg-1,
there was reduction in testosterone and follicle stimulating hormone while on
the other hand, luteinizing hormone was increased mostly with 400 mg kg-1
of metronidazole treatment. Body weight was also found to be significantly reduced
in rats treated with 200 and 400 mg kg-1 of metronidazole. The results
of this study indicate that metronidazole administration (200 or 400 mg kg-1),
for 8 weeks, caused a harmful effect on fertility potentials in male rats. |
|
| |
|
|
| |
| Received:
December 30, 2011; Accepted: June 12, 2012;
Published: June 29, 2012 |
|
|
INTRODUCTION
It has been reported severally in literatures suggesting a possible decline
in human semen quality during the last 50-60 years (Jensen,
2002; Carlson et al., 2003). Approximately
10-15% of couples demonstrate primary infertility and of these a male fact is
identified in approximately 50% of the cases (Cocuzza et
al., 2008). Many factors both extrinsic and environmental factors including
the increased use of antibiotics and anti-effective drugs have been implicated
as potential causes of male infertility (Khaki et al.,
2008). The antifertility effects of this drug have also been reported by
Aranha et al. (2002).
Tenaw and Tsiege (2004) are of the view that since
antimicrobial combination therapy such as metronidazole, quinolones and tetracycline
are among the most prescribed classes of drugs in medicine, there is high possibility
that some of the couples presenting with history of infertility or inability
to conceive may be due to these groups of drugs.
Metronidazole is used extensively and routinely in clinical practice and its
indications has been expanded to include the management of Helicobacter pylori
associated gastric ulcer diseases Crohns disease and Clostridium
difficile diarrhea (Grover et al., 2001).
Metronidazole has been shown to be mutagenic in bacterial assay (Kummerer
et al., 2000). This mutagenic effect of metronidazole is on the premises
of its ability to reduce a nitro group formed by a reactive intermediate that
attacks the nucleic acid of the micro-organism. This inhibits further DNA synthesis
and causes degradation of already existing DNA (Eisenstein
and Schaechter, 2007). This mutagenic activity may have been responsible
for some reproductive toxicity of metronidazole, including the inhibition of
spermatogenesis in rats earlier reported (Sohrabi et
al., 2007).
Sohrabi et al. (2007) in a dose response study,
reported a significant reduction in organ weight and massive degeneration of
germ cells as early as at type-A spermatogonia stage at the dose of 200 and
400 mg kg-1 of metronidazole. In the same vane, Raji
et al. (2007) studied the role of vitamin E on metronidazole induced
antispermatogenic alterations in albino rats using 60 mg kg-1 of
the drugs and its natural reversibility after 8 weeks of cessation of treatment.
This study therefore, is designed to investigate the antifertility potentials
of metronidazole on the male rats using both experimental and therapeutic doses
and to assess the possible counteracting effects of introduction of exogenous
vitamin E and testosterone to this anti-spermatogenic effect. Also to investigate
the reversibility of the mechanism in metronidazole treated rats after 8 weeks
of abstinence.
MATERIALS AND METHODS
Study site: The experimental male Wistar rats were bought and housed
in the animal house located in the College of Health Sciences, Niger Delta University,
Wilberforce Island.
Metronidazole, vitamin E and Testosterone were purchased from Cynflac Pharmacy,
hospital road, Yenagoa.
Animals and treatment: A total of 105 adult male and 50 female Wistar
rats weighing 170±10 g (70-90 day old) were obtained from the Animal
house of the College of Health Sciences, Niger Delta University, Wilberforce
Island. There were maintained in 12 h light and 12 h dark conditions at a temperature
of 27-30°C in the animal house. The standard laboratory chew and tap water
were available ad libitum. After the acclimatization period of two weeks,
the rats were randomly divided into a control and experimental groups. There
were four major groups with 5 subgroups consisting of 5 rats each.
Ethical considerations: The research proposal was submitted to the Ethical
Research Committee of the College of Health Sciences of the University of port-Harcourt
for consideration and approval before commencement of this research work.
Experiment 1: using adult rats fed with 15 mg kg-1 of metronidazole:
In experiment 1, adult male rats weighing 75±5 g, about 70-90 days old
at the commencement of the experiment were used. There were divided into a control
group (Group 1a), a group treated with 15 mg kg-1 of metronidazole
(1b), a group fed with 15 mg kg-1 of metronidazole and 400 mg kg-1
day-1 of vitamin E concurrently for 8 weeks (Group 1c), a group treated
with 15 mg kg-1 of metronidazole and 0.36 mg kg-1 day-1
of testosterone (Group 1d), another group treated with 15 mg kg-1
of metronidazole, 400 mk kg-1 day-1 of vitamin E and 0.36
mg kg-1 day-1 of testosterone concurrently (Group 1e).
A reversal group (Group 1f) was left for 8 weeks after cessation of treatment
with metronidazole to see whether the observed effects were reversible. Each
group had 5 rats randomly divided into the groups. The metronidazole was delivered
as a single dose in 0.1 mL of distilled water by gastric gavage. Female rats
were used to mate with the control and treated male rats to test for fertility
after the treatment.
Experiment 2: using adult rats fed with 30 mg kg-1 of metronidazole:
In experiment 2, adult male and female rats weighing 160±0.5 g, about
70-90 days old at the commencement of the experiment were used. There were divided
into a control group (Group 2a), a group treated with 30 mg kg-1
of metronidazole (2b), a group treated with 30 mg kg-1 of metronidazole
and 400 mg kg-1 day-1 of vitamin E concurrently for 8
weeks (Group 2c), a group treated with 30 mg kg-1 of metronidazole
and 0.36 mg kg-1 day-1 of testosterone (Group 2d), another
group treated with 30 mg kg-1 of metronidazole, 400 mk kg-1
day-1 of vitamin E and 0.36 mg kg-1 day-1 of
testosterone concurrently (Group 1e). A reversal group (Group 1f) was left for
8 weeks after cessation of treatment with metronidazole to see whether the observed
effects were reversible. Each group had 5 rats randomly divided into the groups.
The metronidazole was delivered as a single dose in 0.2 mL of distilled water
by gastric gavage. Female rats were used to mate with the control and treated
male rats to test for fertility after the treatment.
Experiment 3: using adult rats fed with 200 mg kg-1 of metronidazole:
In experiment 3, adult male rats weighing 170±0.9 g, about 70-90 day
old at the commencement of the experiment were used. The rats five in each group
were randomly divided into a control group (Group 3a), a group treated with
200 mg kg-1 of metronidazole (3b), a group fed with 200 mg of metronidazole
and 400 mg kg-1 day-1 of vitamin E concurrently for 8
weeks (Group 3c), a group treated with 200 mg kg-1 of metronidazole
and 0.36 mg kg-1 day-1 of testosterone (Group 3d), another
group treated with 200 mg kg-1 of metronidazole, 400 mk kg-1
day-1 of vitamin E and 0.36 mg kg-1 day-1 of
testosterone concurrently (Group 3e). A reversal group (Group 3f) was left for
8 weeks after cessation of treatment with metronidazole to see whether the observed
effects were reversible. The metronidazole was delivered as a single dose in
0.625 mL of distilled water by gastric gavage. Female rats were used to mate
with the control and treated male rats to test for fertility after the treatment.
Experiment 4: using adult rats fed with 400 mg kg-1 of metronidazole:
In experiment 4, adult male rats weighing 200±5 g, about 70-90 week old
at the commencement of the experiment were used. There were divided into a control
group (Group 4a), a group treated with 400 mg kg-1 of metronidazole
(4b), a group treated with 400 mg kg-1 of metronidazole and 400 mg
kg-1 day-1 of vitamin E concurrently for 8 weeks (Group
4c), a group treated with 400 mg kg-1 of metronidazole and 0.36 mg
kg-1 day-1 of testosterone (Group 4d), another group treated
with 400 mg kg-1 of metronidazole, 400 mk kg-1 day-1
of vitamin E and 0.36 mg kg-1 day-1 of testosterone concurrently
(Group 4e). A reversal group (Group 4f) was left for 8 weeks after cessation
of treatment with metronidazole to see whether the observed effects were reversible.
Each group had 7 rats randomly divided into the groups. The metronidazole was
delivered as a single dose in 0.625 mL of distilled water by gastric gavage.
Female rats were used to mate with the control and treated male rats to test
for fertility after the treatment.
Dose of metronidazole: The dose of 15 and 30 mg kg-1 of body
weight were therapeutic doses (Rossi, 2006), while that
of 400 and 200 mg kg-1 was selected because the LD50 of
metronidazole (p.o.) was determined and it was found to be 5000 mg kg-1.
The 400 mg kg-1 dose taken in this study is less than 1/8 of the
lethal dose and 200 mg kg-1 is less than 1/16 of the lethal dose.
Besides, from literature, several other authors had used similar doses of 200
and 400 mg kg-1 (Sohrabi et al., 2007;
Raji et al., 2007).
Route of administration: The tablet form of metronidazole and vitamin
E were administered through the nasogastric rout while the testosterone injection
was given intramuscularly.
Retrieval of tissues: At termination, the rats were anaesthetized with
ketamine 1 mg kg-1 [intramuscularly (i.m.)], the chest was opened
and blood samples collected by heart puncture. Plasma was separated and stored
at 0°C until ready for hormonal assay.
Body weight: Body weight was taken at the beginning and at termination
of the experiment using electrical weighing machine and the difference calculated
which signifies weight gain.
Fertility test: Only two male rats which were randomly selected from
each group were used for this study. Each male rat was isolated and paired with
a pro-oestrous female rat in the first hours of oestrous cycle that were determined
by vaginal smear examination and was placed in a single cage with each male
rat. On the following day, the female rats were checked after mating to detect
spermatozoa in their vagina by microscopic examination of the vaginal fluid.
Females in which spermatozoa plug were detected the following morning after
mating represented day 1 of gestation. The foetuses were removed by ventral
laparotomy on the 21st day of gestation. The foetuses were counted.
Sperm analysis: The testes from all rats were carefully exposed and
removed. The testes were trimmed free of the epididymides and adjoining tissues.
From each separated epididymis, the caudal part were removed and placed in a
beaker containing 1 mL of physiological saline solution. Each section was then
quickly macerated with a pair of sharp scissors and then left for a few minutes
to liberate its spermatozoa into the saline solution. Sperm motility, concentration
and progressive motility were determined as earlier described by Carey
and Klebanoff (2005).
Hormonal assay: Plasma testosterone, follicle stimulating and luteinizing
hormone were carried out using the immunometrics direct human serum testosterone
enzyme based immunoassay (EIA) kits. The assay was carried out as previously
described by Carey and Klebanoff (2005). The EIA kits
were obtained from immunometrics (London, UK) and contained the respective EIA
substrate reagent and EIA quality control sample. A quality control was carried
out at the beginning and the end of assay to ascertain bias and within batch
variation. The EIA kit used had a sensitivity level of approximately 0.3 nmol
L-1.
Statistical analysis: Data are expressed as Mean±SD and the test
of significance analyzed by students
t-test. The differences were considered significant at p<0.05.
RESULTS
Body weight of control and rats treated with metronidazole: There was
significant gain in body weight of rats treated with 15 and 30 mg kg-1
of metronidazole (p>05) in comparison to the control. Significant weight
gain was not recorded in rats treated with 200 and 400 mg kg-1 (p<0.05).
There was also a significant gain in the groups in which metronidazole was concurrently
administered with vitamin E and or testosterone when compared to the control
(p<0.05) as shown in Fig. 1.
Plasma hormonal levels of Follicle stimulating hormone, luteinizing hormone
and testosterone: Plasma levels of follicle stimulating hormone was not
affected by experimental groups treated with 15 and 30 mg kg-1 of
metronidazole.
|
| Fig. 1: |
A bar chart showing body weight gain of metronidazole treated
rats, Control series a: Fed with experimental group dose of metronidazole
(15, 30, 200 and 400 mg kg-1, respectively), Series b: Fed with
metronidazole and 400 mg kg-1 of vitamin E, series c: Fed with
metronidazole and 0.36 mg kg-1 of testosterone, Series d: Fed
with metronidazole, 400 mg kg-1 of vitamin E and 0.36 mg kg-1
of testosterone, Values are Mean±SD, n = 5, *Not significant at p>0.05 |
| Table 1: |
Serum follicle stimulating hormone (mIU mL-1) of
control and treated experimental rats |
 |
| A: Control, B: Fed with metronidazole, C: Fed with metronidazole
and 400 mg kg-1 of vitamin E, D: Fed with metronidazole and 0.36
mg kg-1 of testosterone, E: fed with metronidazole, 400 mg kg-1
of vitamin E and 0.36 mg kg-1 of testosterone, F: Reversal, Values
are expressed as Mean±standard deviation, n = 5, *Significant at
p<0.05 |
However, FSH was reduced significantly in treatment groups which received
200 and 400 mg kg-1 (4.87±0.90 and 5.08±1.76 mIU mL-1)
compared to the control of 3.34±0.34 mIU mL-1 (p<0.05)
as shown in Table 1.
LH level was significantly increased in experiment 3 and 4 in which rats were
administered with 200 and 400 mg kg-1, respectively. Contrary to
the increased in these groups, rats treated with 30, 200 and 400 mg kg-1
of metronidazole concurrently with testosterone recorded significant decrease
in LH levels (1.61±0.19, 1.75±0.11 and 1.41±0.11 mIU mL-1
as against 1.93±0.14 mIU mL-1 of control) as shown in Table
2.
Serum hormonal level of testosterone was not affected in experimental groups
1 and 2 which were treated with 15 and 30 mg kg-1 of metronidazole
in comparison to the control but the concentration was significantly reduced
with increasing dose of metronidazole.
|
| Fig. 2: |
Sperm analysis of control and metronidazole treated rats,
Series 1; sperm concentration, Series 2; percentage motility, Series 3;
percentage non-motility. A: Control, B: Fed with experimental group dose
of metronidazole (15, 30, 200 and 400 mg kg-1, respectively),
C: Fed with metronidazole and 400 mg kg-1 of vitamin E, D: Fed
with metronidazole and 0.36 mg kg-1 of testosterone, E: Fed with
metronidazole, 400 mg kg-1 of vitamin E and 0.36 mg kg-1
of testosterone, F: Reversal, Values are expressed as mean, n = 5, *Significant
at p<0.05 |
| Table 2: |
Luteinizing hormone (mIU mL-1) of control and treated
experimental rats |
 |
| A: Control, B: Fed with metronidazole, C: Fed with metronidazole
and 400 mg kg-1 of vitamin E, D: Fed with metronidazole and 0.36
mg kg-1 of testosterone, E: Fed with metronidazole, 400 mg kg-1
of vitamin E and 0.36 mg kg-1 of testosterone, F: Reversal, Values
are expressed as Mean±standard deviation, n = 5, *Significant at
p<0.05 |
Although, there was also reduction in testosterone levels in the vitamin E
co-treated groups, the values was not statistically significant (p<0.05)
as shown in Table 3.
Semen analysis of control and experimental rats treated with metronidazole:
The sperm count and motility of experimental group 1 which was administered
with 15 mg kg-1 of metronidazole was not affected in all the sub-groups
in comparison to the control as shown in Fig. 2.
|
| Fig. 3: |
Fertility data of control and metronidazole treated rats,
Series 1: No. of pregnancies, Series 2: No. of fetus. A: Control, B: Fed
with experimental group dose of metronidazole (15, 30, 200 and 400 mg kg-1,
respectively), C: Fed with metronidazole and 400 mg kg-1 of vitamin
E, D: Fed with metronidazole and 0.36 mg kg-1 of testosterone,
E: Fed with metronidazole, 400 mg kg-1 of vitamin E and 0.36
mg kg-1 of testosterone, F: Reversal, Values are expressed as
Mean±standard deviation, No. of mated rats = 2 |
| Table 3: |
Serum testosterone (ng mL-1) of control and treated
experimental rats |
 |
| A: Control, B: Fed with metronidazole, C: Fed with metronidazole
and 400 mg kg-1 of vitamin E, D: Fed with metronidazole and 0.36
mg kg-1 of testosterone, E: Fed with metronidazole, 400 mg kg-1
of vitamin E and 0.36 mg kg-1 of testosterone, F: Reversal, Values
are expressed as Mean±standard deviation, n = 5, *Significant at
p<0.05 |
In experiment 2, there was slight reduction in sperm count in sub-groups treated
with 30 mg kg-1 of metronidazole only, treated with 30 mg kg-1
of metronidazole and vitamin E when compared to the control as illustrated.
In both experimental groups 3 and 4, there was significant reduction in both
sperm count and motility but the lowest count was recorded in experimental group
4.
Fertility test among control and male rats treated with metronidazole:
A dose of 15 mg kg-1 of metronidazole was found not to have adversely
affected the fertility potentials of treated male rats since significant number
of the female rats (>90%) of proven fertility mated with the treated male
rats got pregnant and produced at least an average of six fetuses in all the
sub-groups as shown in Fig. 3. Although, there was mild reduction
in number of pregnant females and the number of fetuses produced in the experimental
group treated with 30 mg kg-1 of metronidazole, it was not significant
when compared to the control group. In experiment 3; in which 200 mg kg-1
of metronidazole alone was administered, did not record any pregnancy. However,
the sub-groups fed with metronidazole and vitamin E or Testosterone, although
the number of pregnancy significantly reduced, recorded 1 each as illustrated.
Experiment group 4 was almost like experimental group 3 but the effects were
more pronounced in terms of number of pregnancy and that of fetuses. There was
a marked improvement in terms of number of pregnancy and that of the fetuses
in all the reversal groups as shown in Fig. 3 below.
DISCUSSION
Testosterone and Follicle Stimulating Hormones (FSH) act on the seminal tubules
to initiate and maintain spermatogenesis (Johnson et
al., 1997). In this study, metronidazole caused a significant decrease
in the testosterone levels after 2 months of the administration. The effects
are more pronounced in the high dose metronidazole treated groups. The reduced
testosterone concentration on metronidazole administration indicates that this
drug suppresses Leydig cell steroidogenesis which tallies with work done by
Amin (2008). It has been documented earlier that intra-peritoneal
administration of metronidazole (400 mg kg-1 day-1), for
30 days, reduced the hormone levels of testosterone, follicle stimulating hormone
and Luteinizing Hormone (LH) in rats (Grover et al.,
2001). Contrary to this work done by Grover et al.
(2001), this study recorded an increase in LH levels in high dose metronidazole.
This indicates that reduction in testosterone levels might have triggered a
negative feedback mechanism on the hypothalamo-pituitary axis. Moreover, Joshie
et al. (1977) found that a single dose of 700 mg kg-1
of 2 thiazolyl-5-nitroimidazole resulted infertility in mice after 3 weeks of
administration, with a return of fertility by week 7. Farombi
et al. (2007) indicated that slight increase of testosterone was
observed after 4 weeks of stoppage of treatment. These increases were still
significantly lower than the control values indicating that a more prolonged
time might be required for probable full restoration of normal level of these
parameters. With the increased duration of time to 8 weeks in the present study,
normal levels of these parameters were nearly or fully restored. The reduction
in both testosterone and gonadotrophins might be as a result of metronidazole
which reaches the blood-testis barrier and gains access to the germinal cells
of the seminiferous tubules. This is in accordance to earlier report by Dixon
and Lee (1973); the blood testis-barrier was possibly an important aspect
when considering reproductive and mutagenic effects of drugs and environmental
chemicals. The permeability characteristics of the blood-testis barrier are
generally similar to those which limit the membrane penetration in the central
nervous system (Okumura et al., 1975).
Metronidazole is distributed to all the tissues including the blood-brain barrier
and seminal fluid (El-Nahas and El-Ashmawy, 2004). The
results of present and earlier studies might explain the direct hazardous effects
of metronidazole on the germ and Leydig cells, that is, a decreased testosterone
secretion after penetration of metronidazole into the blood-testis barrier.
The preventive functions of testosterone on the fertility and testicular function
cannot be overlooked since it has significantly or almost prevented both morphological
and biochemical changes observed in group B animals in this study.
The slightly reduced sperm count in the rats treated with 30 mg kg-1
of metronidazole for 8 weeks might be as a result of feedback control system
on the anterior pituitary and hypothalamus due to the increased serum testosterone
concentration. Although, serum testosterone concentration on it own does not
determine the fate of spermatogenesis, the intratesticular testosterone which
is the seminiferous tubular fluid testosterone does. There is a highly significant
positive correlation between serum LH, FSH and intratesticular testosterone
(Takahashi et al., 1982). These authors stated
that circulating levels of LH is related to intratesticular testosterone (r
= 0.67 p<0.001). This suggests that raised circulating levels of testosterone
can suppress anterior pituitary secretion of LH. Consequently, a suppressed
LH concentration can lead to a reduced intratesticular testosterone which might
be either due to a suppressed activity or reduced quantity of the Leydig cells.
This may eventually lead to suppression of spermatogenesis which tallies with
earlier work done by Ligha and Fawehinmi (2012).
There was a marked reduction of sperm count in the high dose group treated
with either 200 or 400 mg kg-1. The reduced sperm count in these
groups may be as a result of the damage of the spermatogenic cells of the tubular
epithelium where sperm cells, spermatogonia differentiate till they become spermatozoa
(Farombi et al., 2007). The observed damage of
the germinal epithelium and the depletion in the Sertoli cell number recorded
in the previous studies (Ligha and Fawehinmi, 2012),
might have been accounted for the low sperm count in the high dose treated groups.
Results obtained from the low dose (paediatric doses) metronidazole treated
male rats suggest that at the administered dose for the period of treatment
does not significantly interfere with development and maturation of male gonad
morphologically since the rats could still impregnate female rats which were
mated with them. The improvement of fertility in the group treated with metronidazole
and vitamin E shows that to a greater extent, vitamin E act as powerful anti-oxidant
to protect the oxidative stress of metronidazole on the testes because vitamin
E has been described as an excellent lipid soluble chain-breaking antioxidant
(Farombi et al., 2007). The use of vitamin E
in vitro has been also documented to improve sperm motility and viability (Verma
and Kanwar, 1999) which is in consonance with our findings.
CONCLUSION
This study has demonstrated that the effects of metronidazole on fertility
potential is dose depended and it is reversible after 8 weeks of cessation of
treatment. It has also shown that introduction of vitamin E and or testosterone
to an extent protect the deleterious effects of metronidazole on the testis
of rats.
|
|
REFERENCES |
Amin, A., 2008. Ketoconazole-induced testicular damage in rats reduced by Gentiana extract. Exp. Toxicol. Pathol., 59: 377-384. PubMed |
Aranha, O., L. Zhu, S. Alhasan, D.P. Wood Jr, T.H. Kuo and F.H. Sarkar, 2002. Role of mitochondria in ciprofloxacin induced apoptosis in bladder cancer cell. J. Urol., 167: 1288-1294. PubMed |
Carey, J.C. and M.A. Klebanoff, 2005. Is a change in the vaginal flora associated with an increased risk of preterm birth? Am. J. Obstetrics Gynecol., 192: 1341-1346. CrossRef | PubMed | Direct Link |
Carlson, E., A.M. Anderson, J.H. Petersen and N.E. Skakkebaek, 2003. History of febrile illness and variation in semen quality. Hum Reprod., 18: 2089-2092. CrossRef | PubMed | Direct Link |
Cocuzza, M., M.A. Cocuzza, F.M. Bragais and A. Agarwal, 2008. The role of varicocele repair in the new era of assisted reproductive technology. Clinics, 63: 395-404. CrossRef |
Dixon, R.L. and I.P. Lee, 1973. Possible role of the blood-testicular barrier in dominant lethal testing. Environ. Health Perspect., 6: 59-63. PubMed | Direct Link |
Eisenstein, B.I. and M. Schaechter, 2007. DNA and Chromosome Mechanics. In: Schaechter's Mechanisms of Microbial Disease, Schaechter, M., N.C. Engleberg, V.J. DiRita and T. Dermody (Eds.). Lippincott Williams and Wilkins, Hagerstown, MD., USA., ISBN-13: 9780781753425, pp: 28.
El-Nahas, A.F. and I.M. El-Ashmawy, 2004. Reproductive and cytogenetic toxicity of metronidazole in male mice. Pharmacol. Toxicol., 94: 226-231. CrossRef | Direct Link |
Farombi, E.O., S.O. Abarikwu, I.A. Adedara and M.O. Oyeyemi, 2007. Curcumin and kolaviron ameliorate di-n-butylphthalate-induced testicular damage in rats. Basic Clin. Pharmacol. Toxicol., 100: 43-48. CrossRef | PubMed | Direct Link |
Grover, J.K., V. Vats, M. Srinavas, S.N. Das, P. Jha, D.K. Gupta and D.K. Mitra, 2001. Effect of metronidazole on spermatogenesis and FSH, LH and testosterone levels of pre-pubertal rats. Indian J. Exp. Biol., 39: 1160-1162. PubMed | Direct Link |
Jensen, J.T., 2002. Male contraception. Curr. Womens Health Rep., 2: 338-345. PubMed |
Johnson, L., T.L. Blanchard, D.D. Varner and W.L. Scrutchfield, 1997. Factors affecting spermatogenesis in the stallion. Theriogenology, 48: 1199-1216. CrossRef | PubMed |
Joshie, S.R., Y. Bishop and S.S. Epstein, 1977. Chemical Agents Affecting Testicular Function and Male Fertility. In: The Testis, Johnson, W.R., W.R. Gomes and N.H. van Demark (Eds.). Academic Press, New York, USA., pp: 605-627.
Khaki, A., M.G. Novin, A.A. Khaki, M. Nouri, E. Sanati and M. Nikmanesh, 2008. Comparative study of the effects of gentamicin, neomycin, streptomycin and ofloxacin antibiotics on sperm parameters and testis apoptosis in rats. Pak. J. Biol. Sci., 11: 1683-1689. CrossRef | PubMed | Direct Link |
Kummerer, K., Al-Ahmed and V. Mersch-Sundermann, 2000. Biodegradability of some antibiotics, elimination of the genotoxicity and affection of wastewater bacteria in a simple test. Chemosphere, 40: 701-710. Direct Link |
Ligha, A.E. and H.B. Fawehinmi, 2012. Stereological quantification of leydig and sertoli cells: Technique of assessing antifertility potentials of metronidazole. Niger. J. Med., 21: 26-30.
Okumura, K., I.P. Lee and R.L. Dixon, 1975. Permeability of selected drugs and chemicals across the Blood-testis barrier of the rat. J. Pharmacol. Exp. Ther., 191: 89-95. PubMed | Direct Link |
Raji, Y., O.T. Kunle-Alabi, S.B. Olaleye, M.A. Gbadegesin and F.O. Awobajo et al., 2007. Impact of α-tocopherol on metronidazole and tetracycline-induced alterations in reproductive activities of male albino rats. J. Biol. Sci., 7: 41-46. CrossRef | Direct Link |
Rossi, S., 2006. Australian Medicines Handbook Adelaide. Australian Medicines Handbook, Australia.
Sohrabi, D., A. Mohsen and A.M. Ali, 2007. Effect of metronidazole on spermatogenesis, plasma gonadotrophins and testosterone in rats. Iran. J. Reprod. Med., 5: 69-72. Direct Link |
Takahashi, J., Y. Higashi, J. LaNasa, S. Winters, H. Oshima and P. Troen, 1982. Studies of the human testis. XVII. Gonadotropin regulation of intratesticular testosterone and estradiol in infertile men. J. Clin. Endocrinol. Metab., 55: 1073-1080. PubMed |
Tenaw, A. and G.M. Tsiege, 2004. Self-medication and Practice of drug consumers in Addis Ababa: A prospective study. Ethiopian J. Health Sci., 14: 1-11.
Verma, A. and K.C. Kanwar, 1999. Effect of vitamin E on human sperm motility and lipid peroxidation in vitro. Asian J. Androl., 1: 151-154. PubMed |
|
|
|
 |